ROIV - Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% | Benzinga
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in patients with Graves' disease.
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism).
The company says the results show that batoclimab meaningfully exceeded 50% response rates.
Consistent with studies of batoclimab in other indications, 680 mg administered subcutaneously (SC) in the initial cohort demonstrated an IgG reduction of up ...